Cycloserine

證據等級: L5

預測適應症: 7 個

Cycloserine: Evaluation Pending — No TxGNN Predictions Available

One-Sentence Summary

Cycloserine (DB00260) is a broad-spectrum antibiotic known for use in drug-resistant tuberculosis management. The current Evidence Pack contains no TxGNN-predicted indications for this compound, and critical data fields — original indication, mechanism of action, and safety profile — are absent from the pipeline output. A full repurposing evaluation cannot be completed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions generated
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Since the predicted_indications array is empty in this Evidence Pack, no mechanistic repurposing rationale can be presented. The following data gaps directly block analysis:

Original indication is not recorded in the Evidence Pack. The TFDA query returned zero results (query log ID 1), indicating Cycloserine has no regulatory footprint in the queried database. Without a confirmed base indication, the "From X to Y" repurposing framework cannot be applied.

Mechanism of action is not available. The DrugBank query returned a result (query log ID 3), yet MOA data was not populated — suggesting an extraction failure downstream. Without MOA, it is not possible to assess pharmacological overlap with any candidate new indication.

Safety profile is entirely absent. Warnings and contraindications both returned as data gaps despite a successful package insert query (query log ID 4). For a compound with known CNS toxicity risks, this constitutes a blocking issue for any safety-gated repurposing decision.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

New Zealand Market Information

Cycloserine is not currently marketed in New Zealand. No product authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Cycloserine is structurally incomplete — no TxGNN predictions were generated, and three blocking data gaps (original indication, MOA, safety warnings) prevent entry into the standard evaluation workflow.

To proceed, the following is needed:

Run TxGNN prediction pipeline for Cycloserine (DB00260) to generate candidate repurposing indications
Extract MOA from DrugBank — query log confirms a successful DrugBank hit (ID 3); re-run extraction to populate original_moa
Parse package insert safety data — query log confirms a successful TFDA insert retrieval (ID 4); re-run parsing to populate key_warnings and contraindications
Confirm original indication from DrugBank categories or international label (e.g., WHO, FDA) to anchor the "From X" axis of repurposing analysis
Re-generate Evidence Pack after gaps are resolved, then re-submit for full evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.